Published in Molecules on February 12, 2015
Withaferin A Analogs That Target the AAA+ Chaperone p97. ACS Chem Biol (2015) 0.85
Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97. ACS Med Chem Lett (2015) 0.84
Ring of Change: CDC48/p97 Drives Protein Dynamics at Chromatin. Front Genet (2016) 0.81
Strategic role of the ubiquitin-dependent segregase p97 (VCP or Cdc48) in DNA replication. Chromosoma (2016) 0.81
Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway. ACS Med Chem Lett (2015) 0.80
Targeting p97 to Disrupt Protein Homeostasis in Cancer. Front Oncol (2016) 0.79
Oxaspirol B with p97 Inhibitory Activity and Other Oxaspirols from Lecythophora sp. FL1375 and FL1031, Endolichenic Fungi Inhabiting Parmotrema tinctorum and Cladonia evansii. J Nat Prod (2016) 0.77
Perturbation of cellular proteostasis networks identifies pathways that modulate precursor and intermediate but not mature levels of frataxin. Sci Rep (2015) 0.76
Quantitative interaction mapping reveals an extended UBX domain in ASPL that disrupts functional p97 hexamers. Nat Commun (2016) 0.76
Dual Unnatural Amino Acid Incorporation and Click-Chemistry Labeling to Enable Single-Molecule FRET Studies of p97 Folding. Chembiochem (2016) 0.76
Correction: Chapman, E.; et al. Inhibitors of the AAA+ chaperone p97. Molecules 2015, 20, 3027-3049. Molecules (2015) 0.75
Valosin-containing Protein is a Target of 5'-l Fuligocandin B and Enhances TRAIL Resistance in Cancer Cells. ChemistryOpen (2016) 0.75
It's all about talking: two-way communication between proteasomal and lysosomal degradation pathways via ubiquitin. Am J Physiol Cell Physiol (2016) 0.75
Valosin-containing protein (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants. Elife (2017) 0.75
TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion. Oncol Lett (2016) 0.75
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal. Mol Oncol (2016) 0.75
Transmembrane helix hydrophobicity is an energetic barrier during the retrotranslocation of integral membrane ERAD substrates. Mol Biol Cell (2017) 0.75
A Mighty "Protein Extractor" of the Cell: Structure and Function of the p97/CDC48 ATPase. Front Mol Biosci (2017) 0.75
The unfolded protein response: from stress pathway to homeostatic regulation. Science (2011) 15.71
Autophagy in human health and disease. N Engl J Med (2013) 8.71
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet (2004) 7.84
The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature (2001) 7.59
Aberrant rel/nfkb genes and activity in human cancer. Oncogene (1999) 5.62
Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J Cell Biol (2003) 4.35
Activation of a membrane-bound transcription factor by regulated ubiquitin/proteasome-dependent processing. Cell (2000) 3.97
Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol (2009) 3.50
Membrane fusion and the cell cycle: Cdc48p participates in the fusion of ER membranes. Cell (1995) 3.44
Structure of the AAA ATPase p97. Mol Cell (2000) 3.37
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A (2011) 3.20
Cdc48p interacts with Ufd3p, a WD repeat protein required for ubiquitin-mediated proteolysis in Saccharomyces cerevisiae. EMBO J (1996) 3.09
Cdc48 (p97): a "molecular gearbox" in the ubiquitin pathway? Trends Biochem Sci (2006) 2.97
Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nat Struct Biol (2003) 2.93
Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem (1998) 2.80
Diverse functions with a common regulator: ubiquitin takes command of an AAA ATPase. J Struct Biol (2006) 2.66
Conformational changes of p97 during nucleotide hydrolysis determined by small-angle X-Ray scattering. Structure (2005) 2.53
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A (2009) 2.37
Improved structures of full-length p97, an AAA ATPase: implications for mechanisms of nucleotide-dependent conformational change. Structure (2008) 2.36
p97: The cell's molecular purgatory? Mol Cell (2006) 2.23
Cdc48: a power machine in protein degradation. Trends Biochem Sci (2011) 2.08
Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem (2008) 2.07
A stress-responsive system for mitochondrial protein degradation. Mol Cell (2010) 2.05
Allostery: an illustrated definition for the 'second secret of life'. Trends Biochem Sci (2008) 1.99
The crystal structure of murine p97/VCP at 3.6A. J Struct Biol (2003) 1.98
Ubiquitin receptors and ERAD: a network of pathways to the proteasome. Semin Cell Dev Biol (2007) 1.88
A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants. EMBO J (2010) 1.85
A ubiquitin ligase-associated chaperone holdase maintains polypeptides in soluble states for proteasome degradation. Mol Cell (2011) 1.81
Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol (2004) 1.78
Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47. EMBO J (2004) 1.68
Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat Struct Mol Biol (2014) 1.66
ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J Biol Chem (2002) 1.66
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol (2013) 1.65
Quantitative analysis and interpretation of allosteric behavior. Methods Enzymol (2004) 1.65
Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation. Curr Opin Cell Biol (2011) 1.62
Recent advances in p97/VCP/Cdc48 cellular functions. Biochim Biophys Acta (2011) 1.62
Going through the motions: the ATPase cycle of p97. J Struct Biol (2006) 1.61
A major conformational change in p97 AAA ATPase upon ATP binding. Mol Cell (2000) 1.61
The Cdc48 machine in endoplasmic reticulum associated protein degradation. Biochim Biophys Acta (2011) 1.60
Imbalances in p97 co-factor interactions in human proteinopathy. EMBO Rep (2010) 1.55
Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation. Mol Cell Biol (2009) 1.47
Determination of the order of gene function in the yeast nuclear division pathway using cs and ts mutants. Genetics (1982) 1.47
Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin. Mol Biol Cell (2004) 1.44
Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data. Biochem J (2001) 1.44
p97 and close encounters of every kind: a brief review. Biochem Soc Trans (2004) 1.40
Hexamerization of p97-VCP is promoted by ATP binding to the D1 domain and required for ATPase and biological activities. Biochem Biophys Res Commun (2003) 1.38
Tyrosine phosphorylation regulates cell cycle-dependent nuclear localization of Cdc48p. Mol Biol Cell (1998) 1.37
Analysis of nucleotide binding to P97 reveals the properties of a tandem AAA hexameric ATPase. J Biol Chem (2008) 1.36
The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci (2014) 1.32
Structural basis of the unfolded protein response. Annu Rev Cell Dev Biol (2012) 1.31
Characterization of erasin (UBXD2): a new ER protein that promotes ER-associated protein degradation. J Cell Sci (2006) 1.30
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol (2014) 1.29
A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol (2000) 1.28
Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol (2012) 1.27
Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem (2013) 1.25
AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential. J Cell Mol Med (2008) 1.23
D1 ring is stable and nucleotide-independent, whereas D2 ring undergoes major conformational changes during the ATPase cycle of p97-VCP. J Biol Chem (2003) 1.22
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS One (2010) 1.21
Mechanisms of Cdc48/VCP-mediated cell death: from yeast apoptosis to human disease. Biochim Biophys Acta (2008) 1.19
The complexities of p97 function in health and disease. Mol Biosyst (2010) 1.17
Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J Cell Sci (2009) 1.15
Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One (2011) 1.14
Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res (2004) 1.13
Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains. J Mol Biol (2014) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Altered intracellular localization and valosin-containing protein (p97 VCP) interaction underlie ATP7A-related distal motor neuropathy. Hum Mol Genet (2011) 1.09
Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J Biol Chem (2011) 1.08
VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One (2012) 1.08
The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol (2011) 1.08
Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol (2003) 1.04
Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J Med Chem (2013) 1.02
P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett (2013) 1.01
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther (2012) 1.00
Altered intersubunit communication is the molecular basis for functional defects of pathogenic p97 mutants. J Biol Chem (2013) 0.99
Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J Biol Chem (2011) 0.98
Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer. Ann Surg Oncol (2005) 0.97
2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97). Bioorg Med Chem Lett (2010) 0.97
p97-containing complexes in proliferation control and cancer: emerging culprits or guilt by association? Genes Cancer (2010) 0.96
Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS One (2013) 0.93
Structural and functional implications of phosphorylation and acetylation in the regulation of the AAA+ protein p97. Biochem Cell Biol (2010) 0.92
Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis (2012) 0.92
Create and preserve: proteostasis in development and aging is governed by Cdc48/p97/VCP. Biochim Biophys Acta (2013) 0.92
Ubiquitylation in ERAD: reversing to go forward? PLoS Biol (2011) 0.92
A connexin50 mutant, CX50fs, that causes cataracts is unstable, but is rescued by a proteasomal inhibitor. J Biol Chem (2013) 0.92
Expression level of valosin-containing protein (VCP) as a prognostic marker for gingival squamous cell carcinoma. Ann Oncol (2004) 0.91
Structural and functional deviations in disease-associated p97 mutants. J Struct Biol (2012) 0.90
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. Gynecol Oncol (2012) 0.90
Genetic prognostic index influences patient outcome for node-positive breast cancer. Surg Today (2006) 0.89
p97 Homologs from Caenorhabditis elegans, CDC-48.1 and CDC-48.2, suppress the aggregate formation of huntingtin exon1 containing expanded polyQ repeat. Genes Cells (2008) 0.89
Inhibition of protein translocation at the endoplasmic reticulum promotes activation of the unfolded protein response. Biochem J (2012) 0.89
Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. ACS Chem Biol (2012) 0.89
Evaluating p97 inhibitor analogues for their domain selectivity and potency against the p97-p47 complex. ChemMedChem (2014) 0.87
Multiple modes of interaction of the deglycosylation enzyme, mouse peptide N-glycanase, with the proteasome. Proc Natl Acad Sci U S A (2005) 0.86
Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules (2014) 0.85
Functional chromatography reveals three natural products that target the same protein with distinct mechanisms of action. Chembiochem (2014) 0.85
The type II deiodinase is retrotranslocated to the cytoplasm and proteasomes via p97/Atx3 complex. Mol Endocrinol (2013) 0.84
A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression. Oncogene (2014) 0.83
Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3. PLoS One (2012) 0.81
New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells. Cancer Biol Ther (2006) 0.80